Eli Lilly Unveils Latest Clinical Trial Data on Combining Efgartigimod and Tirzepatide

On October 10, Eli Lilly announced new exploratory data from the TOGETHER-PsO3 Phase III clinical trial. The study aimed to evaluate the efficacy and safety of combining efgartigimod with tirzepatide versus efgartigimod monotherapy in adult patients with moderate-to-severe plaque psoriasis who also have obesity or overweight status and at least one other weight-related comorbidity. Results showed that compared to using efgartigimod alone, the combination therapy led to changes in more biomarkers related to both psoriasis disease and metabolism. (Sina Finance)